Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification
出版年份 2015 全文链接
标题
Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 20, Issue 6, Pages 705-720
出版商
Informa Healthcare
发表日期
2015-11-26
DOI
10.1517/14728222.2016.1125469
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
- (2015) A. R. R. Maia et al. ANNALS OF ONCOLOGY
- Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer
- (2015) Leisha A Emens et al. CANCER RESEARCH
- Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer
- (2015) Giuseppe Cancello et al. Clinical Breast Cancer
- Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
- (2015) Taeryung Kim et al. Journal of Breast Cancer
- Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases
- (2015) Anna-Mária Tökés et al. JOURNAL OF CLINICAL PATHOLOGY
- BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
- (2015) Walid T. Khaled et al. Nature Communications
- Therapeutic potential of ERK5 targeting in triple negative breast cancer
- (2015) María Jesús Ortiz-Ruiz et al. Oncotarget
- Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
- (2015) Kyungsoo Ha et al. Oncotarget
- Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
- (2015) Mark Kriegsmann et al. Oncotarget
- Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer
- (2015) Fares Al-Ejeh et al. Oncotarget
- Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
- (2014) María D Cuenca-López et al. BMC CANCER
- Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
- (2014) Jasmeet Chadha Singh et al. BREAST CANCER RESEARCH
- Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators
- (2014) Lyndsay V. Rhodes et al. BREAST CANCER RESEARCH AND TREATMENT
- TMPRSS4: an emerging potential therapeutic target in cancer
- (2014) A L de Aberasturi et al. BRITISH JOURNAL OF CANCER
- Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
- (2014) Fei Ma et al. CANCER LETTERS
- Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
- (2014) Katerina Bouchalova et al. CURRENT DRUG TARGETS
- Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K
- (2014) J. C. Liu et al. EMBO Molecular Medicine
- Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells
- (2014) Ou Huang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
- (2014) Bertrand Allard et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report
- (2014) Agnieszka Kolacinska et al. MOLECULAR BIOLOGY REPORTS
- Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options
- (2014) Pierluigi Gasparini et al. PLoS One
- Geminin Overexpression Promotes Imatinib Sensitive Breast Cancer: A Novel Treatment Approach for Aggressive Breast Cancers, Including a Subset of Triple Negative
- (2014) Zannel Blanchard et al. PLoS One
- The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer
- (2014) Sara Jansson et al. PLoS One
- cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
- (2014) Joohyuk Sohn et al. Journal of Cancer
- Erratum: Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
- (2014) F Al-Ejeh et al. Oncogenesis
- Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
- (2014) Mirco Pistelli et al. Cancers
- Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
- (2013) T. M. A. Abdel-Fatah et al. ANNALS OF ONCOLOGY
- Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
- (2013) B. Gerber et al. ANNALS OF ONCOLOGY
- Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
- (2013) Lee J. McGhan et al. ANNALS OF SURGICAL ONCOLOGY
- Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1
- (2013) Jörg B. Engel et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
- (2013) F Zagouri et al. BRITISH JOURNAL OF CANCER
- Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation
- (2013) Keely M. McNamara et al. CANCER SCIENCE
- B-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain
- (2013) D. Malin et al. CLINICAL CANCER RESEARCH
- The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy
- (2013) S. Chen et al. CLINICAL CANCER RESEARCH
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Novel prognostic markers for patients with triple-negative breast cancer
- (2013) Ling Zhou et al. HUMAN PATHOLOGY
- MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer
- (2013) Yu Jin Kim et al. INTERNATIONAL JOURNAL OF CANCER
- TMPRSS4 as a Poor Prognostic Factor for Triple-Negative Breast Cancer
- (2013) Daye Cheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Elevated Protein Kinase D3 (PKD3) Expression Supports Proliferation of Triple-negative Breast Cancer Cells and Contributes to mTORC1-S6K1 Pathway Activation
- (2013) Bettina Huck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
- (2013) Yong Weon Yi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
- (2013) F. Al-Ejeh et al. JOURNAL OF NUCLEAR MEDICINE
- Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer
- (2013) Mevlude Inanc et al. MEDICAL ONCOLOGY
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
- (2013) R. Joseph Bender et al. PLoS One
- RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs
- (2013) Tyler J. W. Robinson et al. PLoS One
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Expression of Topoisomerase II-α in Triple Negative Breast Cancer
- (2013) Ivana Mrklić et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
- (2013) John Stagg et al. Therapeutic Advances in Medical Oncology
- Expression of androgen receptors in triple negative breast carcinomas
- (2012) Ivana Mrklić et al. ACTA HISTOCHEMICA
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
- (2012) A. Kathleen McClendon et al. CELL CYCLE
- Cytotoxic Effects of Jay Amin Hydroxamic Acid (JAHA), a Ferrocene-Based Class I Histone Deacetylase Inhibitor, on Triple-Negative MDA-MB231 Breast Cancer Cells
- (2012) Mariangela Librizzi et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Overexpression of Cell Cycle Progression Inhibitor Geminin is Associated with Tumor Stem-Like Phenotype of Triple-Negative Breast Cancer
- (2012) Maurizio Di Bonito et al. Journal of Breast Cancer
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
- (2012) Cynthia X. Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
- (2012) Yiqing Tang et al. Journal of Translational Medicine
- Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells
- (2012) R. Rao et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Src: a potential target for the treatment of triple-negative breast cancer
- (2011) D. Tryfonopoulos et al. ANNALS OF ONCOLOGY
- Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
- (2011) Tingting Sun et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
- (2011) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
- (2010) A. A. Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
- (2010) Eun Yoon Cho et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
- (2010) C. K. Anders et al. CLINICAL CANCER RESEARCH
- Small Molecule Inhibitors as Probes for Estrogen and Androgen Receptor Action
- (2010) David J. Shapiro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells
- (2010) Fei-fei Zhou et al. MEDICAL ONCOLOGY
- Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
- (2010) J. Lehmann-Che et al. ONCOLOGIST
- Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks
- (2009) D. Palmieri et al. CLINICAL CANCER RESEARCH
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
- (2009) E. Caldas-Lopes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pattern of metastatic spread in triple-negative breast cancer
- (2008) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
- (2008) Monzur Rahman et al. BREAST CANCER RESEARCH AND TREATMENT
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation